How to buy Kronos Bio (KRON) stock

Kronos Bio, Inc is an other business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio employs 74 staff and has a market cap (total outstanding shares value) of 0.00.

Kronos Bio stock price (NASDAQ: KRON)

Use our graph to track the performance of KRON stocks over time.

Kronos Bio shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$24.41
52-week range	$19.60 - $39.61
50-day moving average	$24.08
200-day moving average	$26.73
Wall St. target price	$42.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Kronos Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Kronos Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kronos Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kronos Bio price performance over time

Historical closes compared with the close of $24.41 from 2021-05-28

1 week (2021-07-16)	N/A
1 month (2021-06-25)	-2.20%
3 months (2021-04-27)	-2.20%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Kronos Bio financials

Gross profit TTM	$0
Return on assets TTM	-15.79%
Return on equity TTM	-39.47%
Profit margin	0%
Book value	$8.19
Market capitalisation	$1.2 billion

TTM: trailing 12 months

Shorting Kronos Bio shares

There are currently 5.0 million Kronos Bio shares held short by investors – that's known as Kronos Bio's "short interest". This figure is 12.5% up from 4.4 million last month.

There are a few different ways that this level of interest in shorting Kronos Bio shares can be evaluated.

Kronos Bio's "short interest ratio" (SIR)

Kronos Bio's "short interest ratio" (SIR) is the quantity of Kronos Bio shares currently shorted divided by the average quantity of Kronos Bio shares traded daily (recently around 499758.2). Kronos Bio's SIR currently stands at 10. In other words for every 100,000 Kronos Bio shares traded daily on the market, roughly 10000 shares are currently held short.

To gain some more context, you can compare Kronos Bio's short interest ratio against those of similar companies.

• Exact Sciences Corporation (EXAS.US): 7.02
• Inovio Pharmaceuticals (INO.US): 7.61
• Moderna (MRNA.US): 1.3

However Kronos Bio's short interest can also be evaluated against the total number of Kronos Bio shares, or, against the total number of tradable Kronos Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kronos Bio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Kronos Bio shares in existence, roughly 90 shares are currently held short) or 0.1143% of the tradable shares (for every 100,000 tradable Kronos Bio shares, roughly 114 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kronos Bio.

Find out more about how you can short Kronos Bio stock.

Kronos Bio share dividends

We're not expecting Kronos Bio to pay a dividend over the next 12 months.

Kronos Bio overview

Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Frequently asked questions

What percentage of Kronos Bio is owned by insiders or institutions?
Currently 17.009% of Kronos Bio shares are held by insiders and 62.229% by institutions. How many people work for Kronos Bio?
Latest data suggests 74 work at Kronos Bio. When does the fiscal year end for Kronos Bio?
Kronos Bio's fiscal year ends in December. Where is Kronos Bio based?
Kronos Bio's address is: 1300 South El Camino Real, San Mateo, CA, United States, 94402 What is Kronos Bio's ISIN number?
Kronos Bio's international securities identification number is: US50107A1043 What is Kronos Bio's CUSIP number?
Kronos Bio's Committee on Uniform Securities Identification Procedures number is: 501052104